Select Page

CAMBRIDGE, Mass., Dec. 17, 2020 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, today announced that it has appointed Meeta Chatterjee, Ph.D., to its Board of Directors.